Dr. Kennedy on RAS as a Target

Perry Kennedy, MD
Published: Monday, May 09, 2016



Perry Kennedy, MD, postdoctoral research fellow, H. Lee Moffitt Cancer Center and Research Institute, discusses RAS as a target as well as the NCI RAS Initiative.

RAS has been thought to be a difficult therapeutic target, Kennedy explains. Since RAS has very shallow binding pockets, it is challenging for small-molecule inhibitors to bind to and attack it.

However, an exciting component of the NCI RAS Initiative, he adds, is that researchers are actively working to attack RAS from different angles, both directly and indirectly, to better understand its behavior.

SELECTED
LANGUAGE


Perry Kennedy, MD, postdoctoral research fellow, H. Lee Moffitt Cancer Center and Research Institute, discusses RAS as a target as well as the NCI RAS Initiative.

RAS has been thought to be a difficult therapeutic target, Kennedy explains. Since RAS has very shallow binding pockets, it is challenging for small-molecule inhibitors to bind to and attack it.

However, an exciting component of the NCI RAS Initiative, he adds, is that researchers are actively working to attack RAS from different angles, both directly and indirectly, to better understand its behavior.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Year in Review™: Reflecting on Recent Evidence for the Treatment of Hematologic MalignanciesFeb 28, 20192.0
Publication Bottom Border
Border Publication
x